Urinalysis Clinical Trial
Official title:
Ketostix® and Keto-Diastix® Performance Study
Verified date | March 2024 |
Source | Ascensia Diabetes Care |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Persons with Diabetes (PWDs), at minimum of (n=120) will successfully collect their urine and test with two Ascensia strip products. The products are: Ketostix and Keto-Diastix.
Status | Completed |
Enrollment | 126 |
Est. completion date | November 30, 2023 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males and females over 18 years of age. - Diagnosed with Diabetes Mellitus (Type 1 or Type 2) - Able to speak, read and understand English (subjects must demonstrate ability to read a paragraph from the first page of the package insert to qualify for the study). - Willing to complete all study procedures. Exclusion Criteria: - Physical, visual, or neurological impairments that would make the person unable to perform urine collection and testing with the urine strips as determined by the PI. - Intake of Vitamin C supplements (multi-vitamins are permitted) - Prior experience testing glucose or ketones in urine with Ketostix and Keto-Diastix Reagent strips. - Currently taking compounds such as mesna (Mesnex) - Currently taking any medications containing azo dyes (e.g., Pyridium, Gantrisin, Gantanol), nitrofurantoin (Macrodantin, Furadantin). - Currently taking medications such as levodopa. - Working for a medical laboratory, hospital or other clinical setting that involves training in the urinalysis lab or use of urinalysis test strips. - Working for a competitive medical device company (Urine Strip manufacturer) or having an immediate family member or living with someone who works for such a company. - A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk (reason for exclusion will be clearly documented by investigator or designee on the study form). |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Ascensia Diabetes Care |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Testing of self collected urine | Number of Participants with results from self collected urine that are within one color block of reference analyzer | Day 1 | |
Primary | Labeling evaluation | Number of Participants with Responses that are a 3,4, or 5 on a 5 point Likert Scale. | Day 1 | |
Primary | Testing of Urine controls | Number of Participants with Reponses that read within one color block. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Terminated |
NCT03801720 -
UltraWee: Ultrasound Bladder Stimulation
|
N/A | |
Completed |
NCT02751671 -
Point-of-care Ultrasound for Clean-Catch Urine Collection in Young Children
|
N/A | |
Recruiting |
NCT06018831 -
Urine and Ultrasound Screening for Kidney Disease in Children
|
N/A |